BridgeBio Pharma Management
Management criteria checks 4/4
BridgeBio Pharma's CEO is Neil Kumar, appointed in Apr 2015, has a tenure of 11.08 years. total yearly compensation is $14.94M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 2.67% of the company’s shares, worth $359.62M. The average tenure of the management team and the board of directors is 5 years and 6.3 years respectively.
Key information
Neil Kumar
Chief executive officer
US$14.9m
Total compensation
| CEO salary percentage | 6.99% |
| CEO tenure | 11.1yrs |
| CEO ownership | 2.7% |
| Management average tenure | 5yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Narrative Update • May 01
BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside
Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.Seeking Alpha • Apr 29
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore
Summary BridgeBio remains a compelling Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics following Pfizer’s patent settlements. Attruby’s peak annual sales are conservatively modeled at $2.2B, with sensitivity up to $4B, underpinned by a protected branded market through mid-2031. BBIO’s late-stage pipeline—infigratinib, encaleret, and BBP-418—offers potential for additional blockbusters, supporting long-term value beyond Attruby. While opex, debt, and execution risks are notable, Attruby’s cash generation is expected to enable deleveraging and sustain R&D momentum within two to three years. Read the full article on Seeking AlphaNarrative Update • Apr 17
BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence
Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.
Narrative Update • Apr 03
BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares
Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.Narrative Update • Mar 20
BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares
The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.Narrative Update • Mar 05
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026
The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.
New Narrative • Feb 22
BridgeBio Pharma (BBIO) From Biotech Blueprint to Commercial Powerhouse
BridgeBio Pharma (BBIO) has successfully transitioned into a commercial-stage juggernaut, with shares trading at $68.14 as of February 22, 2026. The company is currently riding the momentum of its primary growth engine, Attruby (acoramidis) , which reported preliminary 2025 revenues of $362.4 million.
Narrative Update • Feb 19
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.Narrative Update • Feb 05
BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing
Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.Narrative Update • Jan 22
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026
Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.Narrative Update • Jan 07
BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing
Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.Narrative Update • Dec 24
BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead
BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.Narrative Update • Dec 10
BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond
Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.Narrative Update • Nov 26
BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals
BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.Narrative Update • Nov 10
BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions
BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.Narrative Update • Oct 27
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.Narrative Update • Oct 13
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.Narrative Update • Sep 29
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.Narrative Update • Sep 14
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.Narrative Update • Aug 30
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.New Narrative • Aug 10
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.Analysis Article • Aug 09
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
NasdaqGS:BBIO 1 Year Share Price vs Fair Value Explore BridgeBio Pharma's Fair Values from the Community and select...Seeking Alpha • Apr 22
BridgeBio: Early Signs Point To Blockbuster Revenues
Summary BridgeBio Pharma's Attruby shows strong potential in treating ATTR-CM, with a 42% reduction in mortality, competitive pricing, and convenient pill form. Early commercial launch success, high conversion rates, and channel checks suggest significant market share and revenue growth, potentially doubling current analyst estimates. BBIO's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth, with a potential $300 price target. Despite some risks, BBIO's growth prospects and upcoming catalysts make it a Strong Buy, with analysts likely to re-rate the stock higher. Read the full article on Seeking AlphaSeeking Alpha • Feb 07
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
Summary BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite Attruby's promising market entry, BridgeBio's $6.34bn market cap seems high given my expected 2025 revenues of <$500m and the potential need for additional funding. Upcoming pipeline catalysts are limited, making 2025 a critical year for Attruby's market performance against Pfizer's Vyndaqel and Alnylam's Amvuttra. BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until clearer revenue impacts are seen. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Summary Attruby’s recent approval positions BBIO as a direct competitor to PFE’s Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a superior profile in some cases relative to Vyndaqel. BBIO is now also set to receive $500 million in milestone payments related to Attruby’s approval, and I expect they’ll get an additional $105 million from EU and Japan approvals. ATTR-CM is projected to grow rapidly. BBIO believes it can capture 30-40% of that $15-$20 billion future TAM. So I reiterate my “buy on dips” rating for BBIO, as I anticipate 2025 will be a pivotal year for the stock. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$15m | US$1m | -US$725m |
| Sep 30 2025 | n/a | n/a | -US$797m |
| Jun 30 2025 | n/a | n/a | -US$776m |
| Mar 31 2025 | n/a | n/a | -US$668m |
| Dec 31 2024 | US$16m | US$988k | -US$536m |
| Sep 30 2024 | n/a | n/a | -US$439m |
| Jun 30 2024 | n/a | n/a | -US$454m |
| Mar 31 2024 | n/a | n/a | -US$538m |
| Dec 31 2023 | US$12m | US$742k | -US$643m |
| Sep 30 2023 | n/a | n/a | -US$613m |
| Jun 30 2023 | n/a | n/a | -US$573m |
| Mar 31 2023 | n/a | n/a | -US$425m |
| Dec 31 2022 | US$7m | US$1m | -US$481m |
| Sep 30 2022 | n/a | n/a | -US$491m |
| Jun 30 2022 | n/a | n/a | -US$509m |
| Mar 31 2022 | n/a | n/a | -US$596m |
| Dec 31 2021 | US$26m | US$725k | -US$563m |
| Sep 30 2021 | n/a | n/a | -US$535m |
| Jun 30 2021 | n/a | n/a | -US$495m |
| Mar 31 2021 | n/a | n/a | -US$520m |
| Dec 31 2020 | US$10m | US$550k | -US$449m |
| Sep 30 2020 | n/a | n/a | -US$402m |
| Jun 30 2020 | n/a | n/a | -US$346m |
| Mar 31 2020 | n/a | n/a | -US$291m |
| Dec 31 2019 | US$26m | US$503k | -US$261m |
Compensation vs Market: Neil's total compensation ($USD14.94M) is about average for companies of similar size in the US market ($USD14.63M).
Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.
CEO
Neil Kumar (46 yo)
11.1yrs
Tenure
US$14,944,585
Compensation
Dr. Neil Kumar, Ph D., is Executive Chairman of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. He serves as an Independent Director at Maze Therapeutics, Inc. since March 27, 2026.He has been...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.1yrs | US$14.94m | 2.67% $ 359.6m | |
| CFO & President | 1.8yrs | US$5.83m | 0.20% $ 27.2m | |
| Co-Founder | no data | US$1.12m | 0.46% $ 62.6m | |
| Co-Founder | no data | US$1.10m | 0.39% $ 52.0m | |
| Chief Accounting Officer | 3.3yrs | no data | 0.053% $ 7.2m | |
| Chief Scientific Officer | 10.1yrs | US$2.75m | no data | |
| Chairman of Research & Development | 7.3yrs | US$2.01m | no data | |
| Chief Scientific Officer of Oncology | 6.4yrs | no data | no data | |
| Chief Executive Officer of Gene Therapy | no data | no data | no data | |
| Chief Commercial Officer | 5yrs | no data | no data | |
| Chief Regulatory Affairs Officer | 4.3yrs | no data | no data | |
| President & Chief Medical Officer of Cardiovascular and Renal Diseases | 4.2yrs | no data | no data |
5.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: BBIO's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.1yrs | US$14.94m | 2.67% $ 359.6m | |
| Co-Founder | 7.5yrs | US$1.12m | 0.46% $ 62.6m | |
| Co-Founder | 2.6yrs | US$1.10m | 0.39% $ 52.0m | |
| Lead Independent Director | 4.8yrs | US$599.95k | 0.0099% $ 1.3m | |
| Independent Director | 6.3yrs | US$599.95k | 0.0053% $ 715.1k | |
| Independent Director | 7.2yrs | US$599.95k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$599.95k | 0.0046% $ 619.5k | |
| Independent Director | 10.2yrs | US$599.95k | 0.081% $ 11.0m | |
| Director | 10.2yrs | US$599.95k | 0.045% $ 6.1m | |
| Director | 6.4yrs | US$599.95k | 0.0037% $ 491.6k | |
| Independent Director | 5.9yrs | US$649.95k | 0.030% $ 4.0m | |
| Independent Director | 4.8yrs | US$599.95k | 0.0061% $ 825.6k |
6.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: BBIO's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 12:11 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 37 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| William Pickering | Bernstein |
| Jason Zemansky | BofA Global Research |